Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Sagimet Biosciences makes experimental oral drugs that block a fat-making enzyme called FASN, aiming to treat liver disease, acne, and certain cancers.
Sagimet Biosciences is a small drug developer working on pills that shut down a specific fat-making enzyme in the body called FASN, short for fatty acid synthase. Its lead drug, denifanstat, is aimed mainly at MASH, a serious liver disease where fat builds up and inflames the liver. There is no approved FASN-blocking medicine on the market yet, so Sagimet is essentially trying to prove the whole idea works.
Here's the basic problem it's chasing. In MASH and some other diseases, the body cranks up its own fat production when it shouldn't, and that excess fat damages organs. Blocking FASN is meant to turn the fat-making tap down at the source. The same logic extends to acne, where oil glands depend on fat production, and to certain cancers that lean on fat-making to grow.
The catch is that drug development is brutally expensive and slow, and Sagimet doesn't sell anything yet. It funds itself by raising money from investors鈥攖hrough its Nasdaq listing and follow-on share sales鈥攔ather than from customers. Its progress lives or dies on clinical trial results and eventual regulatory approval, and it competes against much larger players chasing the same liver disease, including Madrigal Pharmaceuticals, which already has an approved MASH drug, and Akero Therapeutics. That makes Sagimet a high-risk, high-reward bet: a real scientific idea, but one still unproven in the market.
Saved answer 路 last researched 15 Nov 2026